Abel Hall LLC’s CG Oncology CGON Stock Holding History

Abel Hall LLC’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,357	Closed	-$227K	–	988
2026 Q1	$227K	Buy	+3,357	New	+$190K	0.05%	549

Other funds holding CGON

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

New York State Common Retirement Fund

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

WesBanco Bank Wheeling, West Virginia $4.02B AUM 32.62% 1-Year Est. Return

Handelsbanken Fonder

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return

SBI Okasan Asset Management Tokyo, Japan $3.04B AUM

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Eleva Capital Paris, France $343M AUM

Abel Hall LLC's CGON Position: Q2 2026 in Review

Abel Hall LLC sold out of CG Oncology (CGON) in Q2 2026, closing a stake of 3,357 shares — an estimated $227K sold.

Abel Hall LLC first reported a position in CGON in Q1 2026 and held it in 1 quarter. The position peaked at $227K in Q1 2026. 29 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

Abel Hall LLC reported no remaining CG Oncology position as of Q2 2026 after selling out during the quarter.
Abel Hall LLC sold 3,357 CG Oncology shares in Q2 2026, an estimated $227K.
Abel Hall LLC first reported a position in CG Oncology in Q1 2026 and held it in 1 quarter.
Abel Hall LLC's CG Oncology position peaked at $227K in Q1 2026.
29 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.